OncoMethylome Sciences Announces Licensing and Testing Agreement with Merck KGaA
OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide
Herman Spolders, CEO of OncoMethylome commented, "We are very pleased that Merck has determined that testing for MGMT gene promoter methylation is a very important component of this clinical trial program. This agreement represents another milestone in our efforts to establish the clinical value of methylation biomarkers for aiding physicians in optimizing the treatment decision-making process and confirms market interest in our companion diagnostic products."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.